Familial Spastic Paraplegia
Also known as: Familial Spastic Paraparesis; Hereditary Spastic Paraplegia; Strümpell-Lorrain disease
Familial spastic paraplegia (FSP) describes a group of largely progressive conditions predominantly affecting the legs.
At a clinical level there are two forms of this condition: pure and complicated. The pure form does not have any additional features, whereas the complicated form is very variable with many different additional features. The pure form is more common than the complicated variety.
Last updated January 2015 by Dr P Giunti, Principal Clinical Research Fellow and Honorary Consultant Neurologist, UCL Institute of Neurology and S Nethisinghe, Postdoctoral Research Associate, UCL Institute of Neurology, London, UK.
There are three main features of FSP: the legs become stiff (spasticity) and there is a variable amount of weakness (paraplegia), and muscle cramps and spasms can also be present. The complicated form of FSP can also be associated with other symptoms, such as ataxia, dementia, visual dysfunction or epilepsy, though the presence and severity of additional symptoms varies from person to person.
FSP is caused by degeneration of the upper motor neurons (which help to carry signals from the brain to the muscles) within the brain and spinal cord.
A combination of factors are taken into account when making a diagnosis of FSP: family history, the presence/absence of additional signs and the exclusion of other non-genetic causes of spasticity, which is particularly important in cases caused by a sporadic mutation. Cerebral and spinal magnetic resonance images (MRIs) are used to exclude other conditions. Along with the age at onset, these clinical and genetic data allow clinicians to decide whether to do genetic testing for FSP.
A multidisciplinary treatment regime is used to manage symptoms. There are three main treatment types: physiotherapy/exercise, electrical muscle stimulation and prescription medication. Physiotherapy in the form of regular exercises to keep muscles stretched helps in reducing stiffness and pain. Functional electrical stimulation (FES) delivers electrical impulses directly to certain muscle groups, producing contractions in muscles normally paralysed due to FSP.
Prescription medication may include baclofen (a voluntary muscle relaxant to relax muscles and reduce tone), tizanidine (to treat intermittent spasms) and diazepam or clonazepam (to decrease intensity of spasms). Botulinum toxin (botox) may also be administered to treat spasticity. Botox can reduce spasticity one to two weeks post-injection, with an effect lasting around three to four months.
The chromosomal locations (loci) of many spastic paraplegia genes are now known, although several of the actual genes and mutations causing FSP remain to be identified.
All modes of inheritance (autosomal dominant, autosomal recessive and X-linked) have been described. The most common form of inheritance is autosomal dominant, with the commonest being a pure FSP caused by mutations in the SPG4/SPAST gene on chromosome 2, encoding spastin.
Prenatal testing is only available for pregnancies at increased risk if the disease-causing mutation has already been identified in the family.
HSP Support Group (UK)
Helpline: 01702 218184
Email: via website
The Group is a Registered Charity in England and Wales No. 1109398. It provides information and support for people diagnosed with Hereditary Spastic Paraplegia and their families. It offers grants to members for wheelchairs or scooters.
Group details last updated October 2015.